A Novel Mutation in the Aprataxin (APTX) Gene in an Iranian Individual Suffering Early-Onset Ataxia with Oculomotor Apraxia Type 1 (AOA1) Disease

Nayereh Nouri1, Narges Nouri2, Omid Aryani3, Behnam Kamalidehghan4, Maryam Sedghi1 and Massoud Houshmand*5

1Molecular Genetics Laboratory, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan; 2Genetic Counseling Center, Isfahan; Dept. of Genetics, Special Medical Center, Tehran; 3Dept. of Genetics, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; 4Dept. of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; 5Dept. of Genetics, National Institute for Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

Received 19 May 2012; revised 27 August 2012; accepted 2 September 2012

ABSTRACT

Background: Ataxia with oculomotor apraxia type 1 (AOA1) shows early onset with autosomal recessive inheritance and is caused by a mutation in the aprataxin (APTX) gene encoding for the APTX protein. Methods: In this study, a 7-year-old girl born of a first-cousin consanguineous marriage was described with early-onset progressive ataxia and AOA, with increased cholesterol concentration and decreased albumin concentration in serum. PCR and direct DNA sequencing was performed after DNA extraction. Results: Sequencing analysis revealed a novel homozygous deletion in c.643 and A>T single nucleotide polymorphism in c.641 in exon 6 of the APTX gene [ENST00000379825]. Conclusion: It seems that this region of exon 6 is probably a hot spot; however, no deletions have been reported in exon 6 yet. Iran. Biomed. J. 16 (4): 223-225, 2012

Keywords: Ataxia oculomotor apraxia 1 (AOA1), aprataxin (APTX), Iranian

INTRODUCTION

Ataxia with oculomotor apraxia (AOA, MIM # 208920) is a rare autosomal recessive progressive cerebellar ataxia associated with AOA and severe peripheral neuropathy. There are two types of ataxia with AOA, AOA1 (AOA type 1) and AOA2 (AOA type 2), which are very similar in several clinical features, such as AOA, chorea, myoclonus and neuropathy. The first manifestation of disease is cerebellar atrophy, followed by the inability to coordinate eye-head movements a few years after onset of disease. Besides, progressive cerebellar ataxia, AOA and peripheral neuropathy, hypoalbuminemia and hypercholesterolemia are the hallmark diagnostic features in AOA1 [1-3]. AOA1 is caused by a mutation in the aprataxin (APTX) gene at locus 9p13.3, which encodes for the APTX protein interacting with poly adenosine diphosphate-ribose polymerase-1 [1, 4]. AOA1 shows early onset (mean age of onset: 4.3 years; range: 2-10 years), where the first symptom is progressive gait imbalance followed by dysarthria, mild intention tremor, AOA and peripheral axonal neuropathy [2]. In this study, a 7-year-old girl with ataxia and AOA1 was described.

Patient and molecular analysis.

Clinical features of patient. A 7-year-old girl who was born in Iran from a first-cousin consanguineous marriage with no family history of neurodegenerative disease was described. Her mother had no problem during pregnancy and labor. She was born at term with normal birth weight, normal height and normal head circumstance. She underwent normal childhood development, including walking and speaking, up to 4 years of age. At age 4, a progressive gait imbalance was appeared, followed by intention tremor and dysarthria. When she was referred to the Genetics Department of Special Medical Center at the age of 7, ataxia with intention tremor, dysarthria and AOA were observed. The parents of the patient were informed of the aims of the study and the patient gave her informed consent for the genetics analysis.

*Corresponding Author; Tel.: (+98-21) 4458 0390; Fax: (+98-21) 4458 0399; E-mail: massoudh@nigeb.ac.ir
Neurological and paraclinical examination. Neurological reflexes were exaggerated and electromyography revealed severe axonal sensory-motor neuropathy. MRI of the brain showed cerebellar atrophy. A routine blood examination revealed an increase in cholesterol concentration and a decrease in albumin concentration in serum. Her serum creatine kinase and alpha-fetoprotein levels were normal. The clinical features of the patient have been summarized in Table 1. With regards to the patient’s symptoms, the diagnosis of ataxia with AOA1 was probable, which was later confirmed by molecular diagnosis.

PCR of the APTX gene and direct sequencing. Genomic DNA of the patient and her parents was isolated from peripheral EDTA-treated blood cells by Qiagen DNA Mini kit (cat No: 51304). Genomic DNA (200 ng) of the patient and her parents was subjected to the PCR amplification of coding exons and flanking intronic sequences of the APTX gene. PCR reactions were carried out according to the method and primers described by Habeck and colleagues [5]. The PCR products were analyzed by direct sequencing of DNA fragments amplified by the ABI 3700 capillary sequencer (Macrogen Korea). Sequence results were compared with the published sequence (ENST00000379825). To confirm the results, all procedures of the molecular analysis were double checked.

RESULTS

The patient’s features were in accordance with symptoms that had been reported in the diagnosis of AOA1, which is caused by mutation in the APTX gene. Direct sequencing of all exons of the APTX gene amplified from the patient and her parents revealed a novel homozygous single nucleotide polymorphism (SNP) and a single homozygous nucleotide deletion in exon 6 of the patient’s APTX gene. The parents were heterozygous for the same mutation. The SNP is a single nucleotide change of A to T in c.641, which changes the amino acid tyrosine to phenylalanine at position 214 (Y>F 214) [ENST00000379825]. The nonsense mutation was a single nucleotide (cytosine) deletion located at c.643delC [ENST00000379825] (Fig. 1), which caused a frame shift resulting in a premature stop codon at amino acid 227. Sequence analysis of APTX gene in parents showed that they were also carrier of SNP polymorphism and deletion in exon 6 of APTX gene.

DISCUSSION

In this study, the patient showed two main diagnostic features of early onset ataxia with AOA1 including sever primary motor peripheral neuropathy and AOA. In addition, the total cholesterol and serum albumin levels were higher (>5.6 mmol/L) and lower (< 3.5 g/L) than normal level, respectively. However, her serum creatine kinase and alpha-fetoprotein levels were normal [3]. Regarding to the clinical and paraclinical features, AOA1 was a probable diagnosis for the patient. Clinical diagnosis was confirmed by double check of the molecular test in the affected patient. This is the first report of a single nucleotide change in c.641 A> T [214 (Y>F 214)] [ENST00000379825] and a single nucleotide deletion located at c.643delC [AA227> STOP] [ENST00000379825] in exon 6 of the APTX gene, which caused a frame shift resulting in a premature stop codon at amino acid 227.

APTX consists of seven coding exons. According to The Human Gene Mutation Database, to date, 28 different mutations, deletions and insertions have been
found in the APTX gene [human gene mutation database]. According to Ensemble Database, about 8 other SNP and 5 other mutations have been reported in exon 6, where 3 of them are located in codons 213, 215 and 220, which are very near to our patient’s mutation region in codon 214 [ENST00000379825]. Therefore, it seems that this region of exon 6 is probably a hot spot; however, no deletions have been reported in exon 6 yet [ENST00000379825].

It seems that there is a genotype-phenotype correlation for this disease. For instance, missense mutations of APTX may be associated with a later onset of approximately 9 years. But nonsense or frame shift mutations have an onset age ranging between 2-12 years of age (mean: 4.6 years), that is in accordance with our results [1, 2, 5, 6]. Also, there is a relationship between the type of mutation and severity of cognitive impairments, chorea and dystonia [1, 2, 4, 6], but cerebellar ataxia, cerebellar atrophy and peripheral neuropathy are common symptoms in all patients.

ACKNOWLEDGMENTS

This work was supported by a grant from the Genetics Department, Special Medical Center.

REFERENCES


http://IBJ.pasteur.ac.ir